Trial Profile
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Left ventricular dysfunction; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALLSTAR
- Sponsors Capricor
- 04 Aug 2020 Primary endpoint (relative percentage improvement in infarct size assessed by MRI for the CAP-1002 group compared to the placebo group at Months 6 and 12 post-infusion) has not been met, according to Results published in the European Heart Journal.
- 04 Aug 2020 Results published in the European Heart Journal
- 04 Apr 2019 Status changed from active, no longer recruiting to discontinued.